In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. While AbbVie’s market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results